should i switch from tirzepatide to semaglutide Switching Semaglutide to Tirzepatide: When to

In the GLP-1RA group, no differences in cardiovascular outcomes or all-cause mortality were observed between 2-year-persistent and non-persistent individuals

Participants were randomized to receive subcutaneous semaglutide or placebo once weekly

Ozempic settlement amounts are unlikely to be one-size-fits-all

However, evidence for the impact of GLP-1RAs in individuals with obesity and mental illness is limited

Why doctors urge caution Most safety data about GLP-1 medications and pregnancy comes from animal studies

Discussion Most animal studies demonstrated a beneficial effect of GLP-1RAs and related peptide polyagonists on LFTs, glucose, and lipid metabolism and, most importantly, on hepatic steatosis and inflammation (Tables 1 and 2)